0000000000324411
AUTHOR
Alberto J. Arribas
Screening of fractions from marine sponges and other invertebrates to identify new lead compounds with anti-tumor activity in lymphoma models
Diffuse large B-cell lymphoma (DLBCL) is the commonest type of lymphomas, accounting for 30%-40% of new cases each year. Despite the big improvements achieved in the treatment, still 25–40% of patients still succumb due to refractory or relapsed disease. This highlights the need of new drugs for this cancer. The marine environment has recently been recognized as a source of anti-cancer compounds, as demonstrated by different marine drugs approved by different regulatory agencies (trabectedin, cytarabine, eribulin, plitidepsin) or as components of antibody drug conjugates for lymphoma patients (monomethyl auristatin E in polatuzumab vedotin and brentuximab vedotin). Here, we present a large …
Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma
PI3K kinase has a prominent role in the B-cell receptor signaling. Copanlisib, a pan-PI3K inhibitor with predominant selectivity to PI3Kα and PI3Kδ, is Food and Drug Administration (FDA) approved for the treatment of patients with relapsed or refractory follicular lymphoma, and it is currently under clinical development in other indolent lymphomas including marginal zone lymphoma (MZL). However some patients might eventually relapse because of acquired resistance and so a better understanding of resistance mechanisms is needed. Thus we generated MZL cell lines resistant to copanlisib which could help to design improved therapies
Abstract PO-46: Mechanisms of resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma
Abstract Background: PI3Kδ is expressed in B cells and has a central role in the B-cell receptor signaling. Copanlisib is a highly selective PI3Kδ and PI3Kα inhibitor, and it is currently under clinical development in indolent lymphomas including marginal zone lymphoma (MZL). Copanlisib is Food and Drug Administration (FDA) approved for the treatment of patients with relapsed or refractory follicular lymphoma. Nevertheless, a subset of patients can eventually relapse due to acquired resistance. A better understanding of resistance mechanisms could help to design improved therapies; hence, we generated MZL cell lines resistant to copanlisib. Materials and Methods: Cells were kept on copanlis…